fbpx

molecules of the month

BAY1161909

pro-mitotic selective MPS1 kinase inhibitor

dev. paused for 2nd candidate (BAY1217389)

from 2M cmpd biochem. HTS and SBDD

J. Med. Chem., Apr. 27, 2020

Bayer AG, Berlin, DE

BAY1161909
1 min read

BAY1161909 is one of two clinical candidates disclosed in a single paper from Bayer. The compounds have an interesting anti-cancer mechanism – rather than inhibiting cancer cell growth, they accelerate cancer cell cycle progression, leading to cell death due to a high degree of chromosomal misaggregation. 909 was discovered through an HTS and optimization campaign, while the second candidate was developed from a known starting point. Development on 909 appears to have been paused in favor of the second candidate.


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: